CALR and heart disorder: Hydroxychloroquine has been shown to reduce the recurrence risk of fetal AV block by ~50% in mothers who have had a child previously affected by anti-Ro/SSA mediated fetal C-NL; this drug, started before 10 weeks of gestation, is recommended for secondary prevention of fetal cardiac disease in anti-SSA/Ro-exposed pregnancies [104].